IQVIA Holdings reported strong fourth-quarter 2024 results, with revenue of $3,958 million, an increase of 2.3% on a reported basis and 3.0% at constant currency. This performance exceeded Wall Street estimates, driven by demand for its healthcare data and analytics services.
The Technology & Analytics Solutions (TAS) segment was a key driver, with revenue growing 8.3% reported and 9.5% at constant currency to $1,658 million. The Research & Development Solutions (R&DS) segment saw revenue decrease by 1.3% reported and 1.0% at constant currency to $2,123 million, though bookings exceeded expectations despite a choppy market.
Adjusted diluted EPS for Q4 was $3.12, up 9.9% year-over-year, and adjusted EBITDA increased by 3.1% to $996 million. For the full year 2024, revenue reached $15,405 million, and adjusted diluted EPS was $11.13, up 9.1%.
The R&DS contracted backlog grew to $31.1 billion, a 4.4% increase year-over-year, with $7.9 billion expected to convert to revenue in the next twelve months. The company also announced an increase in its share repurchase authorization by $2,000 million, bringing the total remaining authorization to $3,013 million, signaling confidence in its financial health and commitment to shareholder value.
IQVIA reaffirmed its full-year 2025 guidance, projecting revenue between $15,725 million and $16,125 million, adjusted EBITDA between $3,765 million and $3,885 million, and adjusted diluted EPS between $11.70 and $12.10. This guidance reflects management's outlook despite ongoing market uncertainties.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.